27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Immunic Inc (NASDAQ: IMUX) has announced top-line data from an investigator-sponsored Phase 2 proof-of-concept trial evaluating IMU-838 in primary sclerosing cholangitis (PSC), a rare liver disease characterized by inflamed and narrow bile ducts, thus preventing bile from flowing correctly.
- 27.3% of the patients in the per-protocol population had a clinically relevant reduction of serum alkaline phosphatase higher than 25% at week 24, without an increase in liver biochemistry of more than 33%, as compared to baseline.
- Regarding the secondary objectives of the study, no changes in aspartate aminotransferase, alanine aminotransferase, or total, direct or indirect bilirubin were observed compared to baseline.
- The study also found that IMU-838 is safe and well-tolerated.
- Yesterday, the company announced IMU-838 data from 204 COVID-19 patients who showed clinical activity evidence compared to placebo.
- IMU-838 is an oral selective immune modulator that inhibits activated immune cells' intracellular metabolism by blocking the enzyme dihydroorotate dehydrogenase (DHODH).
- Immunic's management team will host a conference call and webcast today at 8:00 a.m. ET.
- Price Action: IMUX shares are up by 3.99% at $21.10 in the premarket session on the last check Thursday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!